Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN FORTE vs BUCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Tension-type headache
Management of mild to moderate pain,Reduction of fever
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
2-4 hours (terminal); prolonged in renal impairment
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
~85% bound to albumin
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
0.3-0.5 L/kg; distributes primarily into extracellular fluid
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
Oral: 75-90%
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN FORTE vs BUCET, answered by our medical review team.
PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN FORTE and BUCET depend on the specific clinical indication. These are both Barbiturate Combination Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN FORTE and BUCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.